Abstracts
Skip to Late-Breaking Abstracts »
Poster Presentation Dates
All odd numbered posters will be presented on Friday, November 8, 2019, while even numbered posters will be presented on Saturday, November 9, 2019.
Posters will be on display from 7 a.m. - 8 p.m., with the presenting authors required to be at their posters during lunch (12:30 - 2 p.m. on Friday, Nov. 8, and 12:35 - 2:05 p.m. on Saturday, Nov. 9) and also during the poster reception (6:30 - 8p.m. on Friday, Nov. 8, and 7 - 8:30 p.m. on Saturday, Nov. 9).
| # | Title | Authors | Category | Keywords |
|---|---|---|---|---|
| O16 | Avelumab and cetuximab in combination with FOLFOX in patients with previously untreated metastatic colorectal cancer (MCRC) – Final Results of the phase II AVETUX trial (AIO-KRK-0216) | Alexander Stein, MD; Mascha Binder; Eray Goekkurt; Sylvie Lorenzen; Jorge Riera-Knorrenschild; Reinhard Depenbusch; Thomas Ettrich; Steffen Doerfel; Salah Al-Batran; Meinolf Karthaus; Uwe Pelzer; Donjete Simnica; Lisa Waberer; Axel Hinke; Carsten Bokemeyer; Susanna Hegewisch-Becker; Joseph Tintelnot, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy |
| O17 | A Novel Enantio-Specific Cationic Lipid R-DOTAP + HPV16 E6 & E7 Antigens Induces Potent Antigen-Specific CD8+ T Cell Responses In-Vivo in Subjects with CIN and High-Risk Human Papillomavirus Infection | Lauren V. Wood, MD; Lance H. Edwards, MD; Daron G. Ferris, MD; Nicole S. Nevadunsky, MD; Sara Isani, MD; Greg Conn, PhD; Frank Bedu-Addo, PhD; Mark Einstein, MD; | Clinical Trial Completed | Clinical study; Clinical trial; Immune adjuvant; T cell; Vaccine |
| O18 | Neoantigen vaccination targeting shared epidermal growth factor receptor (EGFR) mutations induces clinical and immunological responses in non-small cell lung cancer patients | Gregory A. Lizee, PhD; Fenge Li; Ligang Deng; Amjad Talukder; Kyle Jackson; Arjun Katailiha; Sherille Bradley; Heather Sonnemann; Qingwei Zhou; Caixia Chen; Chong Huo; Yulun Chiu; Matthew Stair; Weihong Feng; Aleksander Bagaev; Nikita Kotlov; Viktor Svekolkin; Ravshan Ataullakhanov; Natalia Miheecheva; Felix Frenkel; Yaling Wang; Minying Zhang; Jason Roszik, PhD; Ling Han; Shuo Zhou; Yan Zhang; Zhenglu Wang; Marie-Andree Forget; Chantale Bernatchez; Cassian Yee, MD; Patrick Hwu, MD; Xueming Du; Gregory A. Lizee, PhD; | Clinical Trial Completed | Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Targeted therapy; Tumor antigens; Tumor microenvironment; Vaccine |
| O19 | Final results from a phase 2 study using off-the-shelf activated natural killer (aNK) cells in combination with N-803, an IL-15 superagonist, in patients with metastatic Merkel cell carcinoma (MCC) | Shailender Bhatia, MD; Candice Church, PhD; Kelly G. Paulson, MD, PhD; Robert H. Pierce, Jr., MD; Paul Nghiem, MD, PhD; John H. Lee, MD; Bridget M. Adcock, BS; Patrick Soon-Shiong, MD; Sunandana Chandra, MD; | Clinical Trial Completed | Adoptive immunotherapy; Checkpoint blockade; Clinical study; Cytokine; NK/NK T cell; Solid tumors; T cell |
| O20 | A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab in checkpoint inhibitor refractory advanced or unresectable melanoma | Alexander N. Shoushtari, MD; Anthony J. Olszanski, MD, RPh; Thomas J. Hornyak, MD; Jedd D. Wolchok, MD, PhD; Sylvia Vetrhus; Karianne Risberg Handeland; Lukasz Kuryk, PhD; Magnus Jaderberg, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Immune monitoring; Tumor microenvironment; Tumor stroma |
| O21 | Safety and clinical activity of avelumab (MSB0010718C), an anti-programed death-ligand 1 (PD-L1) antibody, in recurrent thymic epithelial tumors (TETs) | Arun Rajan, MD; Haobin Chen; Chen Zhao, MD; Shannon Swift; Andrew L. Mammen; Alessandra Brofferio; Emerson Padiernos; Eva Szabo, MD; Udayan Guha; Raffit Hassan, MD; Seth M. Steinberg; Yo-Ting Tsai; Renee N. Donahue, PhD; Jeffrey Schlom; James L. Gulley, MD, PhD, FACP; | Clinical Trial Completed | Autoimmunity; Checkpoint blockade; Clinical trial; Immune monitoring; Immune toxicity; Solid tumors |
| O81 | IMpower110: Interim overall survival (OS) analysis of a Phase III study of atezolizumab (atezo) monotherapy vs platinum-based chemotherapy (chemo) as first-line (1L) treatment in PD-L1–selected NSCLC | Roy Herbst, MD, PhD, Filippo De Marinis, Giuseppe Giaccone, Niels Reinmuth, Alain Vergnenegre, Carlos Barrios, Masahiro Morise, Enriqueta Font, Zoran Andric, Sarayut Geater0, Mustafa Ozguroglu, Simonetta Mocci, Mark McCleland, Ida Enquist, Kim Komatsubara, Yu Deng, Hiroshi Kuriki, Xiaohui Wen, Jacek Jassem, David Spigel, MD | Clinical Trial Completed | Antibody; Biomarkers; Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; Solid tumors |
| P324 | Pan-tumor analysis of the association of cancer and immune biology-related gene expression signatures with response to pembrolizumab monotherapy | Razvan Cristescu, PhD; Michael Nebozhyn, PhD; Chunsheng Zhang, PhD; Andrew Albright, PhD; Julie Kobie, PhD; Lingkang Huang; Qing Zhao, MD PhD; Anran Wang; Hua Ma; Andrea Webber; Petar Jelinic; Mohini Rajasagi; Sandra C. Souza; Raluca Predoiu; Z. Alexander Cao; Junshui Ma; Michael Morrissey; Clemens Krepler, MD; Stephen Keefe; Jonathan Cheng, MD; Vassiliki Karantza; Sukrut Shah; Rodolfo Perini, MD; Antoni Ribas, MD, PhD; Petros Grivas, MD, PhD; David Cescon; Terrill K. McClanahan, PhD; Alexandra Snyder, MD; Mark Ayers, PhD; Jared Lunceford, PhD; Andrey Loboda, PhD; | Clinical Trial Completed | Angiogenesis; Biomarkers; Checkpoint blockade; Clinical study; Gene expression; Immune suppression; Solid tumors; Tumor microenvironment; Tumor stroma |
| P325 | Tumor Infiltrating Lymphocytes (TILs) in triple-negative breast cancer: High Immunoscore is associated with pathological CR in patients receiving neoadjuvant chemotherapy. | Bernardo L. Rapoport, MD; Simon Nayler; Jerome Galon, Dr; T Mlecnik; Teresa Smit; Jacqui Barnard-Tidy; Aurelie Fugon; Marine Martel; Ronald Anderson, Professor; Carol Benn; | Clinical Trial Completed | Chemotherapy; Clinical study; Immunoscore; T cell; Tumor infiltrating lymphocytes (TILs) |
| P326 | A Retrospective Analysis of DNA Plasmid and Peptide-Based Vaccine Therapy in Treatment of HER-2/neu+ Breast Cancer | Aaron W. Stewart, BS; William R. Gwin, MD; Mary L. Disis, MD, FACP; Jennifer S. Childs; James Y. Dai; Doreen M. Higgins, RN, BSN, OCN; Angela Kask; | Clinical Trial Completed | Clinical trial; Targeted therapy; Tumor antigens; Vaccine |
| P327 | Evaluation of PD-L1 and cutoff selection to define a predictive biomarker for pembrolizumab monotherapy in esophageal cancer using KEYNOTE-180 | Mary Savage; Serafino Pantano; Qi Liu; Jared Lunceford, PhD; Peter Kang; Pooja Bhagia, MBBS, MD; Kenneth Emancipator, MD; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Solid tumors |
| P328 | A phase IIB study of Pembrolizumab plus BL-8040 in metastatic pancreatic cancer: Clinical outcomes and biological correlates. | David R. Fogelman, MD; Michael Overman, MD; Robert Wolff; Milind Javle, MD; Shubham Pant, MBBS; Gauri Varadhachary; Rachna T. Shroff; Ignacio Wistuba, MD; Carmelia M. Barreto, PhD; Renganayaki K. Pandurengan, MS; Sandesh Subramanya, PhD; Debora A. Ledesma, PhD; Abi Vainstein-Haras, MD; Ella Sorani, PhD; Tzipora M. Lustig; Osnat Kashtan; Yosi Gozlan; Steven M. Townson, PhD; Jeanne M. Fahey, PhD; James Yao, MD; | Clinical Trial Completed | Antibody; Checkpoint blockade; Chemokine; Clinical trial; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P329 | PolyPEPI1018 off-the shelf vaccine as add-on to maintenance therapy achieved durable treatment responses in patients with microsatellite-stable metastatic colorectal cancer patients (MSS mCRC) | Joleen M. Hubbard, MD; Chiara Cremolini, MD; Rondell Graham, MD; Roberto Moretto, MD; Jessica Mitchell, CNP; Jaclynn Wessling; Eniko Toke; Zsolt Csiszovszki, PhD; Orsolya Lorincz; Levente Molnár; Eszter Somogyi; Mónika Megyesi; Kata Pántya; József Tóth; Péter Páles; István Miklós; Alfredo Falcone, MD; Joleen M. Hubbard, MD | Clinical Trial Completed | Clinical trial; Solid tumors; Vaccine |
| P330 | Results from the completed dose-escalation of the alloSHRINK phase I study evaluating the allogeneic NKG2D-based CAR T-cell therapy CYAD-101 in metastatic colorectal cancer patients | Hans Prenen, MD; Marika Rasschaert, MD; Alain Hendlisz, MD; Leila Shaza, MD; Erik Alcantar-Orozco, MD, PhD; Emilie Cerf, PhD; Florence Renard; Caroline Lonez, PhD; Anne Flament; Jeroen Dekervel, MD; Eric Van Cutsem, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P331 | Results from the completed dose-escalation phase I SHRINK study evaluating the autologous NKG2D-based CAR T-cell therapy CYAD-01 in metastatic colorectal cancer patients | Leila Shaza, MD; Alain Hendlisz, MD; Ahmad Awada, MD, PhD; Jean-Luc Canon, MD; Javier Carrasco; Eric Van Cutsem, MD, PhD; Jeroen Dekervel, MD; Erik Alcantar-Orozco, MD, PhD; Florence Renard; Emilie Cerf, PhD; Caroline Lonez, PhD; Anne Flament; Marc Van den Eynde, MD; Jean-Pascal Machiels, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Chemotherapy; Clinical study; Solid tumors |
| P332 | Cancer vaccine against prostate cancer antigen TARP induces antigen-specific CD8+ T cells with upregulation of activation marker PD1 in patients with decreased PSA velocity in D0 prostate cancer. | Hoyoung M. Maeng, MD; Brittni Moore; Lauren V. Wood, MD; Seth Steinberg; Katherine McKinnon, MS; Masaki Terabe, PhD; Purevdorj Olkhanud; Ira H. Pastan, MD; Jay A. Berzofsky, MD, PhD; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P333 | Timed anti-tumor vaccination during chemotherapy induces strong T-cell immunity and prolonged survival of late stage cervical cancer patients. | Marij J. Schoenmaekers-Welters, PhD; Marij JP. Welters, PhD; Cornelis J. Melief, MD, PhD; Ignace Vergrote; Judith Kroep, MD, PhD; Gemma G. Kenter, MD,PhD; Nelleke Ottevanger; Wiebren AA. Tjalma; Hannelore Denys; Mariette van Poelgeest, MD, PhD; Hans Nijman; Anna KL. Reyners; Thierry Velu; Frederic Goffin; Roy I. Lalisang; Nikki M. Loof; Sanne Boekestijn; Willem Jan Krebber; Leon Hooftman; Sonja Visscher; Brent A. Blumenstein, PhD; Richard B. Stead; Winald R. Gerritsen; Sjoerd H. van der Burg, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Cytokine; Immune monitoring; Solid tumors; T cell; Targeted therapy; Tumor antigens; Vaccine |
| P334 | Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Safety results of a phase I/II study | Christine H. Chung, MD; Marcelo Bonomi, MD; Conor Steuer, MD; Michael Schell; Jiannong Li; Matthew Johnson; Caitlin McMullen; J. Trad Wadsworth; Krupal Patel; Julie A. Kish, MD; Jameel Muzaffar, MD; Kedar Kirtane; James Rocco; Nabil F. Saba, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Targeted therapy |
| P335 | The tumor immune microenvironment and its association with pCR in NRG Oncology/NSABP B-52: Quantification of PD-1, PD-L1, CD8, FOXP3, and CD68 by multiplex fluorescent-immunohistochemistry | Marion E. Joy, PhD; Ying Wang; Rim S. Kim; Nan Song; Ashok Srinivasan; Huichen Feng; Corey Lipchik; Reena S. Cecchini; Samuel A. Jacobs; Joseph P. Costantino; Sandra M. Swain; Eleftherios P. Mamounas; Priya Rastogi; Soonmyung Paik; C. Kent Osborne; Norman Wolmark; Peter C. Lucas; Mothaffar F. Rimawi; Katherine L. Pogue-Geile; | Clinical Trial Completed | Bioinformatics; Checkpoint blockade; Clinical study; Clinical trial; Monocyte/Macrophage; T cell; Tumor microenvironment |
| P336 | Impact of cytokine release syndrome on cardiac function following CD19 CAR-T cell therapy in children and young adults with acute lymphoblastic leukemia | Amita Kulshrestha; Haneen Shalabi, Do; Vandana Sachdev; Douglas R. Rosing; Stanislav Sidenko; Crystal L. Mackall, MD; Brandon Wiley; Daniel W. Lee; Nirali N. Shah; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Immune monitoring; Pediatric tumors; T cell |
| P337 | Survival prolongation by dendritic cell vaccination in combination with OK-432, gemcitabine and/or S-1 in patients with advanced pancreatic cancer | Masahiro Ogasawara, MD, PhD; Shuichi Ota, MD PhD; | Clinical Trial Completed | Clinical trial; Dendritic cell; Tumor antigens; Vaccine |
| P338 | 2-year follow-up from JAVELIN Lung 200, an open-label, randomized, phase 3 study of avelumab vs docetaxel in patients with platinum-treated advanced non-small cell lung cancer (NSCLC) | Fabrice Barlesi, MD, PhD; Mustafa Özgüroglu; Johan Vansteenkiste; David Spigel; James Yang; Hidenobu Ishii; Marina Garassino; Filippo de Marinis; Aleksandra Szczesna; Andreas Polychronis; Ruchan Uslu; Maciej Krzakowski; Jong-Seok Lee; Luana Calabro, MD; Osvaldo Aren Frontera; Barbara Ellers-Lenz; Marcis Bajars; Mary Ruisi; Keunchil Park; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Solid tumors; Targeted therapy |
| P339 | Survival is improved by antigen-specific cytotoxic T lymphocytes (CTL) responses after treatment with the vaccine Tedopi in HLA-A2 positive advanced non-small cell lung cancer (NSCLC) patients | Benjamin Besse, MD PhD; Enriqueta Felip, MD PhD; Giuseppe Giaccone; Rafal Dziadziuszko; Elisabeth Quoix, MD; Werner Hilgers; Federico Cappuzzo; Christophe Borg; Jordi Remon; Nicolas Poirier; Dominique Costantini; Bérangère Vasseur; Santiago Viteri; | Clinical Trial Completed | Antigen presenting cells; Biomarkers; Clinical study; Clinical trial; Immune monitoring; Neoantigens; Solid tumors; T cell; Tumor antigens; Vaccine |
| P340 | Region-focused Deep Survival Learning on PD-L1 stained Tissue Samples for Data-driven Stratification of Durvalumab-treated NSCLC Patients | Nicolas Brieu, PhD; Ansh Kapil; Armin Meier, PhD; Keith E. Steele, DVM, PhD; Marlon C. Rebelatto, DVM, PhD, DACVP; Guenter Schmidt, PhD; | Clinical Trial Completed | Bioinformatics; Biomarkers; Checkpoint blockade; Immune contexture |
| P341 | Activation of toll-like receptors via PS-targeting monoclonal antibodies | Rolf A. Brekken, PhD; | Clinical Trial Completed | Angiogenesis; Antibody; Checkpoint blockade; Clinical study; Immune adjuvant; Immune suppression; MDSC; Tumor infiltrating lymphocytes (TILs); TLR; Tumor microenvironment |
| P342 | Long term outcomes of a Phase I Study with UV1, a Second Generation Telomerase Based Vaccine, in Patients with advanced Non-Small Cell Lung Cancer | Wenche Rasch, PhD; Paal F. Brunsvig, MD PhD; Martha Nyakas, MD; Clau Reisse, MD; Jon Amund Kyte; Hedvig Vidarsdotter Juul; Steinar Aamdal; Gustav Gaudernack, PhD; Else Marit Inderberg; | Clinical Trial Completed | Clinical study; Immune monitoring; Solid tumors; Tumor antigens; Vaccine |
| P343 | Initial results from a Phase II study (TACTI-002) in non-small cell lung cancer, or head and neck cancer patients receiving eftilagimod alpha (LAG-3 fusion protein) and pembrolizumab | Julio Peguero, MD; Enriqueta Felip, MD PhD; Bernard Doger; Margarita Majem; Enric Carcereny; Tim Clay; Pawan Bajaj; Matthew G. Krebs, MD PhD; Frederic Triebel, MD, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Costimulation; Dendritic cell; Monocyte/Macrophage |
| P344 | A randomized multi-center phase 2 study of combined PD-L1/CTLA-4 inhibition with or without radiation in non-small cell lung cancer patients who progressed on PD-(L)1 directed therapy: ETCTN 10021 | Arta M. Monjazeb, MD, PhD; Anita Giobbie-Hurder, MS; Ana Lako; Mark Awad, MD PhD; Ryan D. Gentzler, MD; Carrie Lee; Joleen Hubbard; James L. Abbruzzese, MD; Salma K. Jabbour, MD; Nataliya Uboha; Kevin Stephans; Jennifer Johnson, MD; Haeseong Park; Liza C. Villaruz, MD; Katrina Kao; Elad Sharon, MD, MPH; David Raben, MD; Raymond Mak; Howard Streicher, MD; Helen Chen, MD; Mansoor M. Ahmed, PhD; Scott J. Rodig, MD, PhD; F. Stephen Hodi, Jr., MD; Jonathan Schoenfeld, MD, MPH; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Radiotherapy |
| P345 | PARP inhibition when combined with PD-L1 inhibition has a suppressive effect on T cells in patients with relapsed or recurrent small cell lung cancer | Nobuyuki Takahashi, MD, PhD; Vinodh N. Rajapakse; Min-Jung Lee; Akira Yuno; Sunmin Lee; Sehyun Kim; Rasa Vilimas; Samantha Nichols; Jane B. Trepel; Anish Thomas; | Clinical Trial Completed | Checkpoint blockade; Clinical study; Clinical trial; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell |
| P346 | Comparison of TMEs from melanoma and NSCLC patients refractory or resistant to anti–PD-(L)1 therapies | George Locke; Cherie Taglienti, PhD; Laureen S. Ojalvo; Christoph Helwig, MSc; Alex Rolfe; Olaf Christensen; Isabelle Dussault, PhD; Isabelle Dussault, PhD; | Clinical Trial Completed | Antibody; Biomarkers; Checkpoint blockade; Gene expression; Immune contexture; Immune suppression; T cell; Tumor antigens; Tumor microenvironment |
| P347 | Immunomodulation in tumor and peripheral blood following Toca 511 & Toca FC treatment in patients with solid tumors | Gerald S. Falchook, MD; Jordi Rodon; Shree Venkat; Arthur Donahue; Peder Horner; Amber Thomassen; William Accomando; Maria Rodriquez-Aguirre; Cornelia Bentley; Daniel Hogan; Derek Ostertag; Sharon Yavrom; Thian Khoeh; Douglas Jolly, PhD; Harry Gruber, MD; Jolene S. Shorr; Jaime Merchan; | Clinical Trial Completed | B cell; Clinical trial; Immune monitoring; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P348 | A Phase 1 Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies | Aparna Hegde, MD; Priyamvada Jayaprakash, PhD; Elizabeth Sumner; Di Nguyen; Hira Zain; Sarina A. Piha-Paul, MD; Daniel Karp; Jordi Rodon; Shubham Pant, MBBS; Siqing Fu, MD, PhD; Ecaterina I. Dumbrava, MD; Timothy A. Yap, MD PhD; Vivek Subbiah, MD; Priya Bhosale, MD; Jack P. Higgins, PhD; Eric T. Williams; Thomas F. Wilson; Funda Meric-Bernstam, MD; Michael A. Curran, PhD; David S. Hong, MD; | Clinical Trial Completed | Checkpoint blockade; Chemotherapy; Clinical study; Clinical trial; MDSC; Solid tumors; T cell; Tumor microenvironment; Tumor stroma |
| P349 | Effects of bintrafusp alfa (M7824) and radiation combination therapy on antitumor activity, immune response, and radiation-induced fibrosis in multiple cancer models | Yan Lan, MD; Chunxiao Xu, PhD; Huakui Yu; Guozhong Qin; Bo Marelli; Jin Qi; Rachel E. Fontana; Amit Deshpande; George Locke; Alex Rolfe; Molly H. Jenkins; Joern-Peter Halle; Kin-Ming Lo; | Clinical Trial Completed | Antibody; Checkpoint blockade; Gene expression; Radiotherapy; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P350 | Clinical Signal/Profile in a Phase I Study of T-Cell Receptor (TCR) Affinity-Enhanced Specific T-Cells (TAEST) in Advanced Cancer Patients | Zhaosheng Han, MD, PhD; Xing Zhang, MD; Jian Zhang; Chengzhi Zhou; Haiping Gong; Desheng Weng, MD; Jianchuan Xia, PhD MD; Johnson YN. Lau; Shiyue Li; Weiliang Zhu; Zhaosheng Han, MD, PhD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical study; Clinical trial; T cell; Tumor antigens |
| P351 | Association between response assessment using RECIST and irRECIST in 1765 patients with advanced solid tumors treated with avelumab monotherapy | Juliane Manitz, PhD; Julian Manitz; Peter Eggleton; Marcis Bajars; Oliver Bohnsack, MD, PhD, MBA; James L. Gulley, MD, PhD, FACP; | Clinical Trial Completed | Biomarkers; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P352 | Workflow for Immune Monitoring during Clinical Trials by using unsupervised high dimensional augmented intelligence assisted analysis | Alessandra Metelli, PhD; Carsten Krieg, PhD; Luis E. Cardenas, BS.; Alessandra Metelli, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical study |
| P353 | Phase 1 pilot study of RRx-001 + nivolumab in advanced metastatic cancer (PRIMETIME) | Corey A. Carter, MD; Bryan Oronsky, MD PhD; Mary Quinn; Jane Trepel; Nacer Abrouk, PhD; Jeff Skinner, MD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Coinhibition; Costimulation; Immune adjuvant; Immune suppression; Immune toxicity; Monocyte/Macrophage; Regulatory T cell (Treg cell); T cell |
| P354 | Exploring correlates of clinical and immune response to cancer immunotherapy using FAUST, a novel unbiased cell population discovery method, in whole blood flow cytometry | Steven P. Fling, PhD; Nirasha Ramchurren, PhD; Leonard D'Amico; Martin A. Cheever, MD; Evan Greene; Greg Finak; Raphael Gottardo, PhD; | Clinical Trial Completed | Biomarkers; Clinical study; Immune monitoring; Myeloid cells; T cell; Tumor antigens; Vaccine |
| P355 | Multicenter, open-label, phase 1 study of DSP-7888 Dosing Emulsion (DSP-7888) in patients with advanced malignancies | Alexander I. Spira, MD, PhD, FACP; Morris D. Groves; Aaron Hansen; Wael A. Harb; Kelly K. Curtis, MD; Erina Koga-Yamakawa; Makoto Origuchi; Zhonggai Li; Jose Iglesias; Walid L. Shaib, MD; Alexander I. Spira, MD, PhD, FACP; | Clinical Trial Completed | Clinical study; Clinical trial; Leukemia/Lymphoma; Solid tumors |
| P357 | Phase I/II clinical and immune responses for locally advanced or metastatic pancreatic cancer using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) | Lawrence G. Lum, MD, DSc; Tri Le; Minsig Choi; Archana Thakur, PhD; Matthew Reilly; Paul R. Kunk, MD; Abhinav Deol, MD; Karen Ballen, MD; Tamila Kindwall-Keller, DO; Dana L. Schalk; Ewa Kubicka; Manley Huang, PhD; Philip A. Philip, MD; Hussein Aoun; Gregory Dyson, PhD; Qin Liu; Anthony F. Shields, MD PhD; | Clinical Trial Completed | Adoptive immunotherapy; Antibody; Chemotherapy; Clinical study; Clinical trial; Immune monitoring; Solid tumors; Targeted therapy; Tumor antigens; Tumor microenvironment |
| P358 | Phase 1 trial of NY-ESO-1-specific adoptive T-cell therapy with GSK3377794 in patients with advanced synovial sarcoma | Sandra P. D'Angelo, MD; George Demetri; Brian Van Tine, MD, PhD; Mihaela Druta; John Glod, MD; Warren Chow; Jenna Tress; M. Phillip DeYoung; Aisha N. Hasan, MBBS MD; Yuehui Wu; David C. Turner; Ran Ji; Alexandra Gyurdieva; Dejka Araujo, MD; | Clinical Trial Completed | Adoptive immunotherapy; CAR T cells; Clinical trial; Gene expression; T cell |
| P359 | Tracking and profiling of NY-ESO-1 TCR-transgenic T cells upon adoptive transfer in patients with NY-ESO-1-expressing solid tumors: in vivo differentiation associated with response | Michael Fehlings; Alessandra Nardin, DVM; Faris Kairi; Evan Newell, PHD; Yoshihiro Mihayara; Shinichi Kageyama; Hiroshi Shiku, MD; | Clinical Trial Completed | Adoptive immunotherapy; Clinical trial; Immune monitoring; Solid tumors; T cell; Tumor antigens |
| P360 | The Influence of Durvalumab/Tremelimumab Combination Therapy on Sarcomas Immune Microenvironment Profile in a Phase II clinical trial (NCT02815995) | Edwin R. Parra, MD., PhD; Carmelia M. Barreto, PhD; Ruth Salazar, MD; Cara Haymaker, PhD; Heather Lin; Carmen Behrens, MD; Mei Jiang; Luisa Solis, MD; Krishna R. Pandurenga, MS; Sandesh Subramanya, PhD; Young U. Kim, PhD; Chantale Bernatchez; Jack Lee, PhD; Taylor Tate; Teresa Simmons; Alexander J. Lazar, MD, PhD; Wei-Lien Wang; Zachary A. Cooper, PhD; Jaime Rodriguez-Canales, MD; Jean C. Soria, MD; Anthony P. Conley, MD; Ignacio Wistuba, MD; Neeta Somaiah, MD, MBBS; | Clinical Trial Completed | Clinical trial; Immune contexture; Immune tolerance; Immunoscore; Inflammation; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P361 | Molecular and Immunologic Profiling of CD8+ T Cell Responses in Patients Receiving a Multiple Antigen-Engineered Dendritic Cell Vaccine | Juraj Adamik, PhD; Patricia M. Santos, PhD; Samuel Du, BS; Lazar Vujanovic, PhD; Timothy Howes; Sarah Warren, PhD; Andrea Gambotto, MD; John M. Kirkwood, MD; Lisa H. Butterfield, PhD; | Clinical Trial Completed | Antigen presenting cells; Checkpoint blockade; Clinical trial; Dendritic cell; Gene expression; Immune adjuvant; Immune monitoring; T cell; Tumor antigens; Vaccine |
| P362 | First-line avelumab treatment in patients with metastatic Merkel cell carcinoma: primary analysis after ≥15 months of follow-up from JAVELIN Merkel 200, a registrational phase 2 trial | Sandra P. D'Angelo, MD; Celeste Lebbé; Laurent Mortier; Andrew S. Brohl, MD; Nicola Fazio; Jean-Jacques Grob; Natalie Prinzi; Glenn Hanna; Jessica C. Hassel, MD; Felix Kiecker; Barbara Ellers-Lenz; Marcis Bajars; Meliessa Hennessy, MPH; Paul Nghiem, MD, PhD; | Clinical Trial Completed | Checkpoint blockade; Clinical trial; Solid tumors |
| P364 | A gp100 targeting TCR-based soluble T cell engaging bispecific induces mobilisation and activation of peripheral T cells in patients with metastatic melanoma | Sion M. Lewis, BSc MSc PhD; Mariantonella Vardeu; Jacob Hurst, PhD; Cheryl McAlpine, MSN; | Clinical Trial Completed | Biomarkers; Chemokine; Clinical study; Immune monitoring; Solid tumors; T cell; T cell lineages |
| P365 | A trial to evaluate the immunogenicity and safety of a melanoma helper peptide vaccine plus incomplete Freund’s adjuvant, cyclophosphamide, and polyICLC (Mel63) | Craig L. Slingluff, Jr., MD; Gina R. Petroni, PhD; Kimberly A. Chianese-Bullock, PhD; Nolan A. Wages, PhD; Walter C. Olson, PhD; Kelly T. Smith; Lynn T. Dengel, MD; Anna Dickinson; Caroline Reed; Elizabeth M. Gaughan, MD; William W. Grosh, MD; Varinder Kaur, MD; Nikole Varhegyi; Mark E. Smolkin; Nadejda V. Galeassi; Donna H. Deacon, BS; | Clinical Trial Completed | Antibody; Clinical trial; Immune adjuvant; Solid tumors; T cell; TLR; Tumor antigens; Vaccine |
| P366 | A phase 1 study of NY-ESO-1 vaccine + ipilimumab (ipi) in patients with unresectable or metastatic melanoma | Craig L. Slingluff, Jr., MD; Hassane M. Zarour, MD; Michael Postow, MD; Philip Friedlander, MD PhD; Craig E. Devoe, MD; Ileana S. Mauldin, PhD; Kelly T. Smith; Mary Macri, BSc; | Clinical Trial Completed | Antibody; Clinical trial; Immune adjuvant; Immune monitoring; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); TLR; Tumor antigens; Tumor microenvironment |
| P367 | A multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in post-resection melanoma patients at high risk of recurrence. | Craig L. Slingluff, Jr., MD; Brent A. Blumenstein, PhD; Karl D. Lewis, MD; Robert H. Andtbacka, MD, CM, FACS, FRCSC; John Hyngstrom, MD; Mohammed Milhem, MBBS; Svetomir N. Markovic, MD, PhD; Omid Hamid, MD; Leonel Hernandez-Aya, MD PhD; Tawnya Bowles, MD; Prejesh Philips, MD; Joel Claveau, MD; Sekwon Jang, MD; Jose Lutzky, MD, FACP; Anna Bar, MD; Peter Beitsch, MD; | Clinical Trial Completed | Clinical trial; Solid tumors; Vaccine |
| P856 | AVID200, first-in-class TGF-beta1 and beta3 selective inhibitor: Results of a Phase 1 monotherapy dose escalation study in solid tumors and evidence of target engagement in patients | Timothy Yap, MD PhD , Daniel Araujo, Debra Wood, MD, Jean-François Denis, PhD, Tina Gruosso, PhD, Gilles Tremblay, PhD, Maureen O'Connor-McCourt, Ria Ghosh, Sandra Sinclair, Paul Nadler, MD, Lilian Siu, MD, Nehal Lakhani, MD, PhD | Clinical Trial Completed | Biomarkers; Clinical study; Clinical trial; Solid tumors; Tumor microenvironment; Tumor stroma |
© 2019 Society for Immunotherapy of Cancer (SITC). All rights reserved. SITC Meeting Code of Conduct.
